“减肥双雄”首次“头对头”PK:礼来赢了诺和诺德,高盛:市场早就知道了

华尔街见闻
05 Dec 2024

礼来公司后来居上,与诺和诺德展开激烈的市场份额争夺。减肥药届“双雄”的“拉锯战”加剧! 礼来公司近期公布的一项研究结果显示,其减肥药Zepbound 在与诺和诺德的Wegovy的首次“头对头”临床试验中表现更加优异。 在该项临床测试中,使用Zepbound的参与者在72周内平均减轻了20.2%的体重,而使用诺和诺德的Wegovy的参与者减轻了13.7%。这意味着服用Zepbound的人平均减掉了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10